Advanced clinical protocol
Retatrutide “Triple G”
- Type
- Next-generation triple-hormone-receptor agonist
- Target
- GLP-1, GIP and glucagon receptors
- Action
- Comprehensive metabolic optimisation with substantial weight loss. In phase 2 trials, the highest dose reduced body weight by up to 24% at 48 weeks.
- Ideal for
- Class 3 obesity or significant metabolic comorbidities requiring maximum efficacy.
Triple G 3-month programmeSCR 24,600








